Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Trident II Tritanium Acetabular Shell Outcomes Study
NCT02999009 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to review the performance and success rate of an FDA approved cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study will specifically look at the need to revise the hip replacement after 5 years. This will be compared to how much this happens in patients who have hip replacement with similar cementless acetabular shells.
Conditions Studied
Interventions
- DEVICE Trident II Tritanium Acetabular Shell
Study Locations (9)
New York
- Hospital for Special Surgery — New York
- Northwell Health, Lenox Hill Hospital — New York
Arizona
- Tucson Orthopaedic Institute — Tucson
Florida
- Southeast Orthopedic Specialists — Jacksonville
Illinois
- American Hip Institute — Des Plaines
Louisiana
- Center for Orthopaedics and Spine, LLC — Lake Charles
Michigan
- St. Joseph Mercy Hospital Health System — Ypsilanti
New Jersey
- Rothman Institute — Egg Harbor
North Carolina
- UNC Orthopaedics — Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2031-03 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02999009
The ClinicalTrials.gov registry entry for NCT02999009 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stryker Orthopaedics, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Arthroplasty, Replacement, Hip appearing as the primary indexed condition, and to 1 intervention — of which Trident II Tritanium Acetabular Shell is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02999009 reports 9 study locations spanning 8 distinct geographic areas — top geographies include New York, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02999009 about?
NCT02999009 is a clinical study titled "Trident II Tritanium Acetabular Shell Outcomes Study". The purpose of this study is to review the performance and success rate of an FDA approved cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study will specifically look at the need to revise the hip replacement after 5 years. This will be compared to how much thi...
What is the current status of trial NCT02999009?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 383 participants. The study started on 2017-01-20. Estimated completion is 2031-03.
What conditions does trial NCT02999009 study?
This clinical trial studies the following conditions: Arthroplasty, Replacement, Hip. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02999009?
The interventions under investigation include: Trident II Tritanium Acetabular Shell (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02999009?
This trial is sponsored by Stryker Orthopaedics, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02999009 being conducted?
This trial has 9 study locations across Arizona, Florida, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.